Podcast
Questions and Answers
Which patients are eligible for a shorter all-oral regimen for multidrug- or rifampin-resistant tuberculosis (MDR/RR TB)?
Which patients are eligible for a shorter all-oral regimen for multidrug- or rifampin-resistant tuberculosis (MDR/RR TB)?
- Patients with confirmed resistance to isoniazid
- Patients with extensive pulmonary disease
- Patients with confirmed fluoroquinolone-susceptible disease (correct)
- Patients with a history of exposure to second-line drugs
What is the main toxicity associated with the novel regimen BPaL?
What is the main toxicity associated with the novel regimen BPaL?
- Peripheral neuropathy (correct)
- Myelosuppression
- Pulmonary disease
- Drug-drug interactions
How long was the course of treatment with the BPaL regimen in the study?
How long was the course of treatment with the BPaL regimen in the study?
- 9 months
- 3 months
- 12 months
- 6 months (correct)
What percentage of patients in the study achieved cure with the BPaL regimen?
What percentage of patients in the study achieved cure with the BPaL regimen?
What is the purpose of lobectomy or wedge resection in the treatment of tuberculosis?
What is the purpose of lobectomy or wedge resection in the treatment of tuberculosis?
What is the role of bedaquiline in the BPaL regimen?
What is the role of bedaquiline in the BPaL regimen?
Which of the following is a criterion for offering a shorter all-oral regimen to patients with MDR/RR TB?
Which of the following is a criterion for offering a shorter all-oral regimen to patients with MDR/RR TB?
What is the main adverse effect of linezolid in the BPaL regimen?
What is the main adverse effect of linezolid in the BPaL regimen?
What is the purpose of the shorter MDR-TB regimen?
What is the purpose of the shorter MDR-TB regimen?
How many patients were enrolled in the study of the BPaL regimen?
How many patients were enrolled in the study of the BPaL regimen?
Which drug was approved by the FDA in August 2019 for the treatment of a population of patients with MDR-TB caused by a strain with additional resistance to a fluoroquinolone or a second-line injectable drug?
Which drug was approved by the FDA in August 2019 for the treatment of a population of patients with MDR-TB caused by a strain with additional resistance to a fluoroquinolone or a second-line injectable drug?
What did the WHO suggest about the use of the new 6-9 month pretomanid regimen in late 2019?
What did the WHO suggest about the use of the new 6-9 month pretomanid regimen in late 2019?
Which drug was used at a reduced daily dose and/or for a shorter period of time in a dose-blinded study reported in 2021?
Which drug was used at a reduced daily dose and/or for a shorter period of time in a dose-blinded study reported in 2021?
What is the name of the regimen being tested by the Global Alliance that is composed of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide?
What is the name of the regimen being tested by the Global Alliance that is composed of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide?
In a phase 2B trial, MDR-TB patients treated with the BPaMZ regimen became culture-negative within 8 weeks of treatment how many times faster than drug-sensitive TB patients treated with the standard regimen?
In a phase 2B trial, MDR-TB patients treated with the BPaMZ regimen became culture-negative within 8 weeks of treatment how many times faster than drug-sensitive TB patients treated with the standard regimen?
What is the aim of testing the BPaMZ regimen for both MDR-TB and drug-susceptible TB?
What is the aim of testing the BPaMZ regimen for both MDR-TB and drug-susceptible TB?
Where is the ideal setting for providing care to seriously ill MDR-TB patients?
Where is the ideal setting for providing care to seriously ill MDR-TB patients?
When should hospitalization be considered for MDR-TB patients?
When should hospitalization be considered for MDR-TB patients?
What is associated with significant reductions in mortality risk and AIDS-related events in HIV-associated TB patients?
What is associated with significant reductions in mortality risk and AIDS-related events in HIV-associated TB patients?
What is the reduction in mortality rates associated with early initiation of ART during anti-TB treatment?
What is the reduction in mortality rates associated with early initiation of ART during anti-TB treatment?
Flashcards are hidden until you start studying
